First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion StudyRyan J. Sullivan, Bob T. Li, Jeffrey A. Sosman et al.|Cancer Discovery|2017Cited by 418
Identifying tumor origin using a gene expression-based classification map.Phillip Buckhaults, Ie‐Ming Shih, Zhen Zhang et al.|PubMed|2003Cited by 119